1. Scrip
  2. >>Business

Viatris Buys Two Eye Specialists, Setting The Stage For ‘Phase Two’ Of Its Growth Plan

Acquisitions Could Add $1bn To Net Sales By 2028

 
• By Jessica Merrill

The company will buy Oyster Point Pharma and Famy Life Sciences for $700m to $750m in total as management tries to move the business towards more innovation.

bud
Viatris hopes to build a new business in ophthalmology • Source: Shutterstock

Two years after Viatris Inc. was established from the merger of Mylan Pharmaceuticals Inc. with Pfizer Inc.'s Upjohn business, the former generics company is getting ready to begin the second phase of its growth strategy, starting with the acquisition of two potential new growth levers in ophthalmology. Viatris announced on 7 November the acquisition of Oyster Point Pharma, Inc. and Famy Life Sciences, two eye care companies, for an aggregate of $700m to $750m in cash.

The two acquisitions mark an important inflection point for Viatris as the management team attempts to position the company to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.